Mount Sinai School of Medicine

Temple University

Icahn School of Medicine at Mount Sinai

Clavis Pharma Asa

James F Holland

Micsunica Platica

Lewis R Silverman

E Premkumar Reddy

Julius G Bekesi

Ovidiu Platica

Peter H Tsang

John Roboz

Imre Weisz

Jian-Dong Jiang

George J Bekesi

Beatriz Pogo

M V Ramana Reddy

Finn Myhren

Marit Liland Sandvold

Ole Henrik Eriksen

Svetlana Zinzar

Ovidu Platica

M V Reddy

Methods and compositions are provided for treating myelodysplastic syndrome and acute myeloid leukemia, wherein the composition comprises at least one compound according to Formula I: wherein Ris selected from the group consisting of &#x2014;NH, &#x2014;NH&#x2014;CH&#x2014;COH, &#x2014;NH&#x2014;CH(CH)&#x2014;COH, and &#x2014;NH&#x2014;C(CH)&#x2014;COH, or a pharmaceutically acceptable salt of such a compound; and a DNA methyltransferase inhibitor, or a pharmaceutically acceptable salt thereof.

Composition and methods for the treatment of myelodysplastic syndrome and acute myeloid leukemia

The present invention is directed toward compounds of Formula (I) as follows: wherein, where the crossing dashed line illustrates the bond formed joining Rto the molecule of Formula (I);

Azacytidine analogues and uses thereof

Methods and compositions are provided for treating proliferative disorders, wherein the composition comprises at least one compound according to Formula I: wherein Ris selected from the group consisting of &#x2014;OH, &#x2014;NH, &#x2014;NH&#x2014;CH&#x2014;COH, &#x2014;NH&#x2014;CH(CH)&#x2014;COH, and &#x2014;NH&#x2014;C(CH)&#x2014;COH, or a pharmaceutically acceptable salt of such a compound; and an anthracycline, e.g. doxorubicin, or a pharmaceutically acceptable salt thereof, or a platin, e.g. oxaliplatin, or a pharmaceutically acceptable salt thereof.

Composition and methods for the treatment of proliferative diseases

The present invention relates to a gene selectively expressed in malignant cells and associated with the development of androgen resistance in prostate cancer. Levels of the gene, termed 'PAR' (for Prostate Androgen Regulated), its RNA transcript, and its protein product are all present at increased levels in malignant cells, such as breast cancer and prostate cancer cells. The present invention provides for PAR nucleic acid molecules and proteins, for antibodies that specifically bind to PAR proteins, and to methods for diagnosing and treating cancers that utilize such molecules.

PAR, a novel marker gene for breast and prostate cancers

The present invention provides for haloacetoamido, benzoic acid derivatives having anti-tumorigenic activity. Examples of the haloacetoamido, benzoic acid derivatives include 3-chloroacetoamido, benzoylurea, 3-bromoacetoamido, benzoylurea, 3-iodoacetoamido, benzoylurea, ethyl-3-chloroacetoamido, benzoate, ethyl-3-bromoacetoamido, benzoate and ethyl-3-iodoacetoamido, benzoate. Intermediates for synthesizing the derivatives, along with methods of making and using the derivatives, are also provided.

Aminobenzoic acid derivatives having anti-tumorigenic activity, methods of making and using the same

Haloacetoamido, benzoic acid derivatives having anti-tumorigenic activity are inclosed. Examples of the haloacetoamido, benzoic acid derivatives include 3-chloroacetoamido, benzoylurca, 3-bromoacctoamido, benzoylurea, 3-todoacetoamido, benzoylurca, ethyl-3-chloroacetoamido, benzoate, ethyl-3-bromoacetoamido, benzoate and ethyl-3-iodoacetoamido, benzoate. Intermediates for synthesizing the derivatives, along with method of making and using the derivatives, are also provided.

Aminobenzoic acid derivatives having anti-tumorigenic activity methods of making and using the same

The present invention relates to materials and methods for diagnosing breast cancer in humans. It is based, at least in part, on the discovery that a substantial percentage of human breast cancer tissue samples contained nucleic acid sequences corresponding to a portion of the mouse mammary tumor virus env gene. In contrast, such sequences were absent in almost all other human tissues tested.

Detection of mammary tumor virus-like sequences in human breast cancer

The present invention is directed to pituitary differentiation factor (PDF), a pituitary factor that is capable of differentiating cells including breast cancer and prostatic cancer cells. Isolated nucleic acids encoding PDF and related vectors and host cells are also provided. Restoration of differentiating ability to malignantly transformed cells provides a modality of cancer therapy. The isolated and purified PDF of the invention is accordingly useful in the treatment of breast and prostatic cancer.

Pituitary differentiaton factor and methods of use thereof

Pituitary differentiation factor and methods of use thereof

The present invention relates to materials and methods for diagnosing breast cancer in humans. It is based, at least in part, on the discovery that a substantial percentage of human breast cancer tissue samples contained nucleic acid sequences corresponding to a portion of the mouse mammary tumor env gene. In contrast, such sequences were absent in almost all other human tissues tested.

Detection of mammary tumor virus env gene-like sequences in human breast

A new technique is disclosed for assaying for the presence of invasive cancer. While based on leukocyte adherence inhibition, it is improved by using relatively long lived radio-labeled leukocytes, fractionation of the leukocytes to separately treat T-cells and monocytes and by providing for human plasma or serum in the incubation medium.

Growing community of inventors

Scarsdale, NY, United States of America

James F Holland